The Benefits of Hippotherapy for Patients With Parkinson's Disease of 75 Years

NCT06500182 | Recruiting

• 1 other identifier: 2020-A03105-34
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

There is no cure for Parkinson's disease, resulting in an interest for research in this domain. Non pharmacological measures remain essential, specifically physical activity. Hippotherapy is a nonconventional method which uses the horse in addition to standard care. The goal being to improve or maintain the gains of the person through cognitive, sensorial and motor stimulation, with the aim of improving quality of life and maintaining independence. With this in mind, the researchers propose to evaluate quality of life as the main criterion, using the PDQ8 scale validated for this disease. The researchers hope results will lead to the coverage of the costs of non-conventional therapies such as hippotherapy by social security services.

Conditions

Parkinson Disease

Outcome Measures

Primary Outcomes (1)

• Assessing quality of life in Parkinson's disease by PDQ8 questionnaires

  changes from baseline in PDQ8 scores, which contain 8 items given a score between 0 (never) and 4 (always) maximum control; range, 0 to 32.

  06 weeks

Secondary Outcomes (4)

• Assessing Parkinson's disease Motor disorders

  06 weeks

• Assessing Parkinson's disease severity of the non-motor symptoms

  06 weeks

• Assessing Parkinson's disease Postural and walking disorders

  06 weeks

• MRI in diagnosis differential in Parkinson's disease

  day 0

Study Arms (1)

hippotherapy sessions

EXPERIMENTAL

Patients will benefit from the hippotherapy sessions in additional to continuing to receive traditional care ,To evaluate any differences between the initial visit and the evaluation following 6 weeks in PDQ8 scores, which contain 8 items given a score between 0 (never) and 4 (always)

Other: hippotherapy sessions

Interventions

hippotherapy sessions OTHER

Patients benefit from the hippotherapy sessions in additional to continuing to receive traditional care.

hippotherapy sessions

Eligibility Criteria

• Age: 75 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Age ≥ 75 years with PD according to Movement Disorders Society criteria (2015).
• Clinical diagnosis of Alzheimer's disease
• Has been on stable antiparkinsonian treatment for less than 3 months.
• Ability to understand the principle of the study as well as its risks.
• Written consent to participate in the trial.
• Have social insurance
• Agree to comply with all safety procedures during the study and its duration.
• Ability to understand and freely give consent
• Patient affiliated to social security or entitled beneficiary
• Autonomy preserved

You may not qualify if:

• age \<75 years
• refusal to sign consent
• MOCA \<23
• Presence of major behavioural problems that do not allow MRI to be performed under optimal conditions
• Subjects unable to receive informed information, unable to participate in the study as a whole
• Subjects with a diagnosis of atypical parkinsonian syndrome (Lewy body disease, progressive supranuclear palsy, multisystem atrophy, cortico-basal degeneration, etc.).
• A classic contraindication to an MRI examination: claustrophobia, presence of incompatible foreign material,
• Subjects who have practised horse riding at a high level, animal phobias, wish to stop studying, etc.
• No affiliation to a social security scheme
• Antiparkinsonian treatment has not been stable for at least 3 months.
• People under protective supervision (guardianship, curatorship)
• People under family guardianship are also excluded, as are people for whom a mandate for future protection has been activated.

Sponsors & Collaborators

• Central Hospital Saint Quentin: lead

Study Sites (1)

Centre Hospitalier de Saint-Quentin;

Saint-Quentin, Aisne, 02100, France

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Officials

• Jadwiga ATTIER, PHD

  CH SAINT-QUENTIN

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jadwiga ATTIER, PHD

CONTACT

0323065707; a.attier@ch-stquentin.fr

Abdelkrim BOULANOUAR, M

CONTACT

03323067861; a.boulanouar@ch-stquentin.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 20, 2021
• First Posted: July 15, 2024
• Study Start: July 1, 2023
• Primary Completion: July 1, 2024
• Study Completion: July 1, 2024
• Last Updated: July 17, 2024

Record last verified: 2024-07

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)